Ms. Maggie Massam, Head of Business Development, Clinical Practice Research Datalink (CPRD) expresses that the business from clinical trials is going to be good at Bioasia 2015. She said “There are a lot of Indian companies in clinical trial space, ready to use new ways. The timing is good for both Indian companies and for us. We are very optimistic that we will have a good business.”
Commenting on the clinical trials and safety regulations in India, she said that among the main things that they have been doing, helping companies with the post-product launch was the main. When a company launches new pharmaceutical product, they have to have a drug safety monitoring. They have to observe if drugs are safe even after the clinical trials. What their organization has is anonymous data on patients who are taking the medications. So after a while research studies can be done to investigate those patients to see whether or not the drugs truly are safe. It’s very important for all companies who are producing pharmaceutical products to have drug safety work and their organization enables them to do that with the data available.
Watch the video to see what more Ms. Maggie Massam has to say on the clinical trail business, how conducive are the regulatory policies, where the clinical trail sector is heading and much more..